Loading...
Leflunomide — Export Intelligence Report
2025-Q4 · TransData Nexus
PHARMA TRADE INTELLIGENCE
INDIA EXPORT INTELLIGENCE REPORT
Leflunomide
2025-Q4
Comprehensive analysis of India’s leflunomide export trade — suppliers, buyers, prices, routes, and every shipment record.
84
Shipments
$1.59M
Trade Value
21
Suppliers
32
Buyers
27
Countries
Scan for online report
Talk to our analyst: +91 95950 78788
https://transdatanexus.com/pharmaceutical/leflunomide
01
PART I — OVERVIEW
Executive Summary
At-a-glance KPIs, key findings, and strategic positioning of India’s leflunomide trade — 2025-Q4
KEY TAKEAWAY
Leflunomide 2025-Q4 exports total $1.6M across 27 countries, with ZYDUS LIFESCIENCES LTD commanding 26.5% market share.
TOTAL SHIPMENTS
84
2025-Q4
EXPORT VALUE
$1.6M
FOB USD
TOTAL QUANTITY
15.6M
units shipped
INDIAN SUPPLIERS
21
unique exporters
GLOBAL BUYERS
32
unique importers
DESTINATIONS
27
countries
MEDIAN UNIT PRICE
$0.288
per unit
TOP-5 SHARE
85.2%
of total USD
BRANDED SHARE
64.3%
54 shipments
DOSAGE FORMS
2
product types
6 KEY FINDINGS
1
ZYDUS LIFESCIENCES LTD is India's #1 Leflunomide exporter with $422.3K (26.5% market share).→ §5, Indian Supplier Rankings
2
Leflunomide reached 27 countries, with United States as the top destination ($433.4K).→ §4, Global Destination Map
3
Market concentration is moderate (HHI: 1685) — top 10 suppliers control 98.8% of exports.→ §5, Indian Supplier Rankings
4
90.6% of buyers (29 of 32) source from a single Indian supplier — potential poaching opportunities.→ §6, Global Buyer Rankings
5
Tablet dominates (99.2%) across 2 dosage forms.→ §7, Price Benchmarks
6
27 countries have ≤5 Indian suppliers — easy-entry markets for SME exporters.→ §9, Strategic Opportunities
WHO THIS REPORT IS FOR
S SUPPLIERS (Indian pharma exporters)
- See which buyers your competitors are shipping to, at what price, through which ports
- Identify buyers that are single-sourced (poaching opportunities)
- Benchmark your pricing and catalog vs the Top 25
B BUYERS (global importers)
- Discover which Indian exporters supply this product and what they sell
- Benchmark the price you are paying vs the market median by country and dosage
- Identify alternative suppliers with proven exports to similar destinations
Figure 1.1 ZYDUS LIFESCIENCES LTD leads in volume — how do 21 exporters compare on price × volume?
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Every bubble is one Indian leflunomide exporter. X-axis = shipment count; Y-axis = average unit price; bubble size = total revenue. Dashed lines split at the median — exporters in the top-right (Bulk Leaders) combine high volume with premium pricing.
HOW TO READ THIS REPORT
60 seconds
Scan this page — KPIs, thesis, flagship chart, top findings
5 minutes
Read every Key Takeaway line across §1–§9
30 minutes
Read sections tagged for your role ([S] or [B]) end-to-end
In depth
Drill into §10 for your country · supplier / buyer directories at end
02
PART I — OVERVIEW
About This Report
Data sources, methodology, trust signals, and what this Leflunomide report covers
KEY TAKEAWAY
Every figure in this report is grounded in real commercial leflunomide trade records. Data comes from official customs filings and public trade sources, runs through a multi-layer quality process, and lands in a clean, consistent report you can rely on.
S FOR SUPPLIERS
Every competitor benchmark, market share figure, and buyer list in this report comes from verified commercial shipments — not surveys or estimates. Use them with confidence when planning your next pitch.
B FOR BUYERS
Every supplier profile, price benchmark, and trade route in this report reflects what that supplier actually ships — real volumes, real destinations, real prices. Use them to qualify and compare Indian leflunomide suppliers.
§2.1 Reporting parameters · the scope of this 2025-Q4 Leflunomide India trade report
Product scope
Leflunomide
All variants merged — branded and generic formulations of leflunomide
Time period
2025-Q4
October, November, December 2025 — a single-quarter snapshot
Data sources
Official & public trade records
Government customs filings, public trade databases and licensed commercial feeds
Geography
India origin → global
Indian sea and air ports shipping to destination markets worldwide
Currency
USD (FOB)
Declared Free-on-Board value at the Indian port of loading
Shipments analysed
84
Every commercial leflunomide trade record in the period, aggregated and deduplicated
§2.2 Our quality process · Figure 2.1
Figure 2.1 From raw trade records to a clean report — the four quality pillars.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Raw trade data (left) flows through four quality checks — source verification, format standardisation, entity matching, and deduplication — to produce the clean, reliable data (right) behind every chart and table in this report.
§2.3 Trust signals · what you can rely on in the numbers you read
DATA COVERAGE
10M+
Pharmaceutical trade records across the full TransData Nexus platform.
COUNTRIES
150+
Origin and destination countries covered in the global pharma trade database.
DATA ACCURACY
99.9%
Validation rate on core fields — supplier, buyer, product, quantity, value.
UPDATE FREQUENCY
Daily
Platform refresh cadence. This report is a snapshot from the same live data.
§2.4 Limitations · what the data does and does not tell you
WHAT THIS DATA DOES AND DOES NOT SAY
- Prices are at the Indian port of loading (FOB), not the final delivered cost in the destination country. Freight, insurance, import duty and local margin are not included.
- This is a single-quarter snapshot. Multi-quarter trends, year-over-year growth and historical comparisons are available on the full platform.
- A small number of records have incomplete transport mode or destination port fields; these appear blank in the shipment register but are still counted in totals.
- This report is a commercial intelligence tool, not a legal audit. For high-stakes decisions, cross-reference with the underlying trade records via the full platform.
03
PART II — MARKET STRUCTURE
Quarterly Trade Overview
Monthly trends, regional performance, and ranking shifts — 2025-Q4
KEY TAKEAWAY
2025-Q4 followed a mixed: Oct $337.5K, Nov $948.0K, Dec $307.2K. Shipment counts rose across the quarter.
S FOR SUPPLIERS
Track which months your competitors were most active, which destinations rose or fell, and whether the Nov dip hit your segment. The bump charts show rank movement — watch for rivals climbing past you.
B FOR BUYERS
Identify whether your current Indian supplier maintained steady shipments through the quarter, or whether they pulled back. Steady suppliers during dips signal reliable partnerships.
1
$337.5K
Oct USD
17 shipments
2
$948.0K
Nov USD
+180.9% MoM
3
$307.2K
Dec USD
-67.6% MoM
4
Mixed
Q4 growth shape
Oct → Nov → Dec
Fig 3.1 Nov rose 180.9% in USD but shipment count kept climbing.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Blue bars = monthly USD. Orange line = shipment count. When bars drop but line rises, average shipment value fell. Insight: Oct opened at $337K, making it the middle month by value.
Fig 3.2 Q4 cumulative USD reached $1.6M.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: The curve shows the running total across the quarter. A steeper slope means that month contributed more revenue. Insight: The curve’s steepest section reveals which month drove the most trade value.
Fig 3.3 $611K rise in Nov, $641K decline in Dec.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Blue bars = absolute monthly value. Red = month-over-month loss; green = gain. Insight: Trade grew steadily across the quarter.
Fig 3.4 Regional breakdown by month — which corridors swung most?
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Each coloured layer is one destination region. Layer height = USD in that month. Insight: The top region contributed the most, while the smallest region had the least volume.
§3.1 Monthly summary
| Oct | $337K | 17 shipments |
| Nov | $948K | 40 shipments |
| Dec | $307K | 27 shipments |
| Q4 Total | $1.6M | 84 shipments |
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
Fig 3.5 Top 10 destination countries by monthly USD rank — who’s rising?
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Each line traces a country’s monthly rank. Lines crossing = rank swaps. Insight: Sri Lanka held #1 throughout the quarter.
Fig 3.6 Top 10 Indian exporters by monthly USD rank.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Each line traces a supplier’s monthly rank. Flat = stable position; crossing = rank change. Insight: EMCURE PHARMACEUTICALS LTD maintained its leading position.
04
PART II — MARKET STRUCTURE
Global Destination Map
Which countries import leflunomide from India, how much they buy, and who supplies each market
KEY TAKEAWAY
United States absorbs 27.2% of India’s 2025-Q4 leflunomide trade ($433.4K). Beyond the top 10 destinations, 27 countries have fewer than 5 Indian suppliers each — white-space markets where new entrants face minimal competition. Asia has 12 destination countries, the widest regional diversity.
S FOR SUPPLIERS
Use the flow map and lanes table to see which destinations your competitors dominate. For small and mid-size suppliers: look beyond the leading markets — the 27 countries in the long tail have fewer than 5 Indian suppliers each and low competitive barriers.
B FOR BUYERS
Find your country on the map to see how much leflunomide India ships to your market, who the top suppliers are, and whether you’re in a concentrated or competitive corridor.
Asia
$393K
24.7% of trade
12 countries · 40 shipments
Europe
$443K
27.8% of trade
6 countries · 22 shipments
Americas
$751K
47.1% of trade
6 countries · 16 shipments
Africa
$6K
0.4% of trade
2 countries · 3 shipments
Oceania
$551
0.0% of trade
1 countries · 3 shipments
Fig 4.1 United States is the #1 corridor ($433K) — 27 flow arcs from India radiate across 5 continents.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: The world map shows every country colored by how much Indian leflunomide it receives (light = low, dark = high). Orange arcs radiate from India to the top 27 destinations; arc thickness = USD value. All destinations are labeled with country name + USD.
§4.1 Top 10 bilateral trade lanes (India → destination) with top Indian suppliers
| # | Destination | Total USD | Ships | #1 Indian supplier | USD | #2 Indian supplier | USD | #3 Indian supplier | USD |
|---|---|---|---|---|---|---|---|---|---|
| 1 | United States | $433K | 10 | ZYDUS LIFESCIENCES LTD | $422K | ALEMBIC PHARMACEUTICALS LTD | $11K | — | — |
| 2 | Germany | $259K | 13 | ALEMBIC PHARMACEUTICALS LTD | $259K | — | — | — | — |
| 3 | Ecuador | $194K | 1 | CAPLIN POINT LABORATORIES LTD | $194K | — | — | — | — |
| 4 | Myanmar | $148K | 6 | TORRENT PHARMACEUTICALS LTD | $105K | KUSUM HEALTHCARE PVT LTD | $43K | IPCA LABORATORIES LTD | $62 |
| 5 | United Kingdom | $135K | 3 | EMCURE PHARMACEUTICALS LTD | $135K | — | — | — | — |
| 6 | Sri Lanka | $93K | 2 | TORRENT PHARMACEUTICALS LTD | $85K | USV PVT LTD | $8K | — | — |
| 7 | Uzbekistan | $75K | 1 | KUSUM HEALTHCARE PVT LTD | $75K | — | — | — | — |
| 8 | Chile | $51K | 1 | EMCURE PHARMACEUTICALS LTD | $51K | — | — | — | — |
| 9 | Nepal | $47K | 7 | TORRENT PHARMACEUTICALS LTD | $47K | — | — | — | — |
| 10 | Canada | $42K | 1 | CIPLA LTD | $42K | — | — | — | — |
Table 4.1 — Top 10 destination countries ranked by trade value, with the largest Indian suppliers for each market.
Fig 4.2 Asia leads at 24.7% of USD — but United States is the single largest market.
Region → country treemap
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Column width = region USD share. Within each column, cells are stacked by country, height = share within region.
§4.2 Destination concentration
27.2%
#1 country share
United States alone
73.4%
Top 5 share
5 of 27 countries
98.0%
Top 15 share
Long tail of 12 countries = 2.0%
HHI 1401
Destination HHI
Competitive spread
27
Countries served
Global pharma reach from India
12
Asia countries
Widest regional diversity
Source: TransData Nexus trade data platform
05
PART III — WHO’S IN THIS MARKET
Indian Supplier Rankings & Profiles
21 Indian exporters ranked by value — profiles, portfolios, and competitive intelligence
KEY TAKEAWAY
ZYDUS LIFESCIENCES LTD ($422.3K, 26.5% share) and ALEMBIC PHARMACEUTICALS LTD ($312.5K) together control 46.1% of India’s 2025-Q4 leflunomide trade. The top 5 suppliers hold 85.2%. 21 companies shipped at least once.
S FOR SUPPLIERS
Find your rank, your competitors’ ranks, and the gap in USD/share between you. The profile pages show each top supplier’s buyer portfolio, dosage mix and route map — your competitive-intelligence toolkit.
B FOR BUYERS
Find potential Indian leflunomide suppliers ranked by size, catalog breadth and destination reach. The profile pages reveal which suppliers have proven trade lanes to your region.
Fig 5.1 ZYDUS LIFESCIENCES LTD leads by $110K over ALEMBIC PHARMACEUTICALS LTD — top 20 Indian exporters ranked by trade value
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Each bar = one Indian supplier ranked by USD. The (#N) shows their rank by shipment count — mismatches reveal pricing strategy. Insight: DERRIC WOOD is #16 by value but #4 by volume.
Fig 5.2 ALEMBIC PHARMACEUTICALS LTD also leads by shipment count (19) but ranking shifts for volume-heavy players
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Same suppliers re-ranked by shipment count. The (#N) shows their rank by USD value. Insight: DERRIC WOOD moves from #4 by volume to #16 by value — fewer but higher-value shipments.
05
PART III — WHO’S IN THIS MARKET
Supply Landscape — Archetypes & Concentration
How India’s 21 leflunomide suppliers split into strategic segments
KEY TAKEAWAY
6 suppliers (25%) generate 93.6% of total trade value. The market splits into four archetypes: Market Leaders, High-Value specialists, Volume players, and a long tail.
Fig 5.3 ZYDUS LIFESCIENCES LTD and ALEMBIC PHARMACEUTICALS LTD sit in the leaders zone — high volume AND high value.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Each bubble is one Indian supplier. X-axis = shipment count (log scale); Y-axis = total USD value (log scale); bubble size = revenue. Blue dashed lines split at the median. Market Leaders (top-right) combine high volume with high value. Premium Niche (top-left) ship fewer but higher-value consignments. Volume Players (bottom-right) compete on quantity. Long-Tail (bottom-left) are small or occasional exporters. Conclusion: the log scale reveals clear strategic clusters — use this map to identify where your company sits relative to competitors.
Fig 5.4 25% of suppliers = 93.6% of USD — classic concentration.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Top bar = supplier %, bottom bar = USD %. The gap = market concentration.
Product variety — how many formulations each supplier ships
| # | Supplier | Dosage forms | Countries | USD |
|---|---|---|---|---|
| 1 | ALEMBIC PHARMACEUTICALS LTD | 2 | 5 | $312K |
| 2 | ZYDUS LIFESCIENCES LTD | 1 | 1 | $422K |
| 3 | TORRENT PHARMACEUTICALS LTD | 1 | 5 | $243K |
| 4 | CAPLIN POINT LABORATORIES LTD | 1 | 1 | $194K |
| 5 | EMCURE PHARMACEUTICALS LTD | 1 | 2 | $187K |
| 6 | KUSUM HEALTHCARE PVT LTD | 1 | 4 | $133K |
| 7 | CIPLA LTD | 1 | 1 | $42K |
| 8 | ANH PHARMACEUTICALS PVT LTD | 1 | 1 | $24K |
| 9 | ASPO PHARMACEUTICALS LLP | 1 | 1 | $10K |
| 10 | USV PVT LTD | 1 | 1 | $8K |
Table 5.1 — The more dosage forms a supplier ships, the more versatile their manufacturing capability.
05
PART III — WHO’S IN THIS MARKET
Supply Landscape — India Origin Geography & Concentration
Which Indian cities and states are the leflunomide manufacturing hubs
KEY TAKEAWAY
Baddi and Gujarat together account for $700K of India’s 2025-Q4 leflunomide trade.
Fig 5.5 Baddi (2 exporters, $388K) and Gujarat (1 exporters, $312K) are India’s leflunomide capitals.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Orange bubbles mark major pharma hub cities; bubble size = USD value. Every hub labeled.
§5.1 Supplier concentration metrics
85.2%
Top 5 share
5 of 21 suppliers
98.8%
Top 10 share
10 of 21 suppliers
93.6%
Top 25% share
6 suppliers = 94% USD
HHI 1685
Supplier HHI
Moderate
21
Total suppliers
shipped Leflunomide in 2025-Q4
20+ cities
Indian hubs
Baddi and Gujarat lead
§5.2 Coming next: 3 exporter deep-dive profiles
Each of the top 3 suppliers gets a dedicated 2-page profile with:
- 6 KPI cards — trade value, shipments, countries, buyers, avg ship value, branded share
- Dosage form breakdown — what formulations they ship
- Monthly trend — Oct / Nov / Dec trajectory
- Trade flow map — supplier → country → importer connections
- Buyer portfolio with lock-in analysis
SUPPLIER PROFILES IN THIS REPORT
| #1 | ALEMBIC PHARMACEUTICALS LTD | $312K |
| #2 | TORRENT PHARMACEUTICALS LTD | $243K |
| #3 | KUSUM HEALTHCARE PVT LTD | $133K |
#2
EXPORTER PROFILE #1 OF 3
ALEMBIC PHARMACEUTICALS LTD
Gujarat · India’s #2 leflunomide supplier by USD · 2025-Q4
2025-Q4 USD
$312K
19.6% market share
SHIPMENTS
19
avg $16K/ship
COUNTRIES
5
destination markets
BUYERS
6
6 single-sourced
BRANDED
42%
of shipments
DOSAGE FORMS
2
product types
TOP 5 DESTINATIONS
Germany is the #1 market at $259K (83% of trade), followed by Netherlands at $33K. 5 countries served.
| # | Country | USD | Ships | Share |
|---|---|---|---|---|
| 1 | Germany | $259K | 13 | 83.0% |
| 2 | Netherlands | $33K | 3 | 10.7% |
| 3 | United States | $11K | 1 | 3.5% |
| 4 | Denmark | $5K | 1 | 1.7% |
| 5 | France | $4K | 1 | 1.1% |
MONTHLY TREND
Nov peaked at $187K. Dec was the weakest at $0.
PRODUCT MIX
Tablet dominates at 96% of trade. filmtablets (3.8%) and others are secondary formulations.
TOP BUYERS · 6/6 LOCKED IN
6 of 6 buyers source exclusively from this supplier — high lock-in with low competitive threat.
| Buyer | Country | USD | Status |
|---|---|---|---|
| STADAPHARM GMBH | Germany | $222K | ⚠ Locked |
| ALIUD PHARMA GMBH | Germany | $37K | ⚠ Locked |
| ALLOGA (NEDERLAND) B.V… | Netherlands | $33K | ⚠ Locked |
| J. KNIPPER & COMPANY | United States | $11K | ⚠ Locked |
| NOMECO HEALTHCARE LOGI… | Denmark | $5K | ⚠ Locked |
| CSP COURNON | France | $4K | ⚠ Locked |
#2
EXPORTER PROFILE #1 OF 3 — TRADE FLOW MAP
ALEMBIC PHARMACEUTICALS LTD — Supplier → Country → Importer
5 destination countries, top 5 importers per country
Fig 5.P1.3 Germany absorbs $259K — the thickest ribbon.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Left = Indian supplier. Middle = destination countries (ordered by USD). Right = importers within each country. Ribbon thickness = USD value; color = country. Every node labeled with name + USD + ships. Showing top 5 destinations and up to 2 importers per destination.
#3
EXPORTER PROFILE #2 OF 3
TORRENT PHARMACEUTICALS LTD
Ahmedabad. Gujarat · India’s #3 leflunomide supplier by USD · 2025-Q4
2025-Q4 USD
$243K
15.2% market share
SHIPMENTS
11
avg $22K/ship
COUNTRIES
5
destination markets
BUYERS
5
5 single-sourced
BRANDED
100%
of shipments
DOSAGE FORMS
1
product types
TOP 5 DESTINATIONS
Myanmar is the #1 market at $105K (43% of trade), followed by Sri Lanka at $85K. 5 countries served.
| # | Country | USD | Ships | Share |
|---|---|---|---|---|
| 1 | Myanmar | $105K | 1 | 43.1% |
| 2 | Sri Lanka | $85K | 1 | 35.0% |
| 3 | Nepal | $47K | 7 | 19.5% |
| 4 | Kenya | $5K | 1 | 1.9% |
| 5 | Zimbabwe | $1K | 1 | 0.5% |
MONTHLY TREND
Nov peaked at $135K. Oct was the weakest at $1K.
PRODUCT MIX
Tablet dominates at 100% of trade.
TOP BUYERS · 5/5 LOCKED IN
5 of 5 buyers source exclusively from this supplier — high lock-in with low competitive threat.
| Buyer | Country | USD | Status |
|---|---|---|---|
| JDS CO LTD | Myanmar | $105K | ⚠ Locked |
| HATTON NATIONAL BANK PLC | Sri Lanka | $85K | ⚠ Locked |
| PHARMACHEM PVT LTD | Nepal | $47K | ⚠ Locked |
| MEDOX PHARMACEUTICALS … | Kenya | $5K | ⚠ Locked |
| PHARMACEUTICAL AND CHE… | Zimbabwe | $1K | ⚠ Locked |
#3
EXPORTER PROFILE #2 OF 3 — TRADE FLOW MAP
TORRENT PHARMACEUTICALS LTD — Supplier → Country → Importer
5 destination countries, top 5 importers per country
Fig 5.P2.3 Myanmar absorbs $105K — the thickest ribbon.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Left = Indian supplier. Middle = destination countries (ordered by USD). Right = importers within each country. Ribbon thickness = USD value; color = country. Every node labeled with name + USD + ships. Showing top 5 destinations and up to 1 importers per destination.
#6
EXPORTER PROFILE #3 OF 3
KUSUM HEALTHCARE PVT LTD
Kusum Healthcare Private Limited · India’s #6 leflunomide supplier by USD · 2025-Q4
2025-Q4 USD
$133K
8.4% market share
SHIPMENTS
6
avg $22K/ship
COUNTRIES
4
destination markets
BUYERS
4
3 single-sourced
BRANDED
67%
of shipments
DOSAGE FORMS
1
product types
TOP 4 DESTINATIONS
Uzbekistan is the #1 market at $75K (56% of trade), followed by Myanmar at $43K. 4 countries served.
| # | Country | USD | Ships | Share |
|---|---|---|---|---|
| 1 | Uzbekistan | $75K | 1 | 56.2% |
| 2 | Myanmar | $43K | 3 | 32.2% |
| 3 | Kazakhstan | $10K | 1 | 7.2% |
| 4 | Ukraine | $6K | 1 | 4.4% |
MONTHLY TREND
Oct peaked at $86K. Dec was the weakest at $0.
PRODUCT MIX
Tablet dominates at 100% of trade.
TOP BUYERS · 3/4 LOCKED IN
3 of 4 buyers source exclusively from this supplier — high lock-in with low competitive threat.
| Buyer | Country | USD | Status |
|---|---|---|---|
| FE BARAKA DORI FARM LLC | Uzbekistan | $75K | ⚠ Locked |
| J.D.S CO LTD | Myanmar | $43K | 2 sup. |
| LLP DARI-PHARM (KAZAKH… | Kazakhstan | $10K | ⚠ Locked |
| GLADPHARM LTD | Ukraine | $6K | ⚠ Locked |
#6
EXPORTER PROFILE #3 OF 3 — TRADE FLOW MAP
KUSUM HEALTHCARE PVT LTD — Supplier → Country → Importer
4 destination countries, top 5 importers per country
Fig 5.P3.3 Uzbekistan absorbs $75K — the thickest ribbon.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Left = Indian supplier. Middle = destination countries (ordered by USD). Right = importers within each country. Ribbon thickness = USD value; color = country. Every node labeled with name + USD + ships. Showing top 4 destinations and up to 1 importers per destination.
06
PART III — WHO’S IN THIS MARKET
Global Buyer Rankings & Intelligence
32 importers across 27 countries — who is buying Indian leflunomide and how much
KEY TAKEAWAY
The demand side is dramatically more fragmented than supply: the top 25 importers together hold only 95.2% of total USD. 91% of buyers source from a single Indian supplier — a vast pool of lock-in candidates.
S FOR SUPPLIERS
Find the importers buying from your competitors. The rankings reveal who has volume, who pays well, and who sources from multiple Indian suppliers (potential pitch targets).
B FOR BUYERS
See where you rank among global importers of Indian leflunomide. Compare your USD and shipment count against peers in your country and dosage segment.
Fig 6.1 ZYDUS PHARMACEUTICALS USA INC is the #1 importer at $378K (23.7%) — top 25 by trade value
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Each bar = one global importer ranked by USD.
Fig 6.2 Re-ranked by shipment count — compare with Fig 6.1 for divergences
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Same 25 importers re-ranked by shipment count.
§6.1 Sourcing diversity — how many Indian suppliers does each buyer use?
91%
Single-source
29 buyers rely on exactly 1 Indian supplier
3%
Dual-source
1 buyers use 2 Indian suppliers
6%
Multi-source (3–4)
2 buyers diversified across 3–4
0%
Broad-source (5+)
0 buyers with 5+ Indian suppliers
06
PART III — WHO’S IN THIS MARKET
Single-Source Buyers & Price Benchmark
Lock-in opportunities grouped by country + where each buyer sits on the price spectrum
KEY TAKEAWAY
These importers source leflunomide from exactly one Indian supplier. For each one, the table shows the incumbent, price, and dosage.
S FOR SUPPLIERS
This is your target list. Each row is a buyer locked into one competitor. Offer 5–10% better pricing to win the second-source slot.
B FOR BUYERS
If you see your company here, you are fully dependent on one Indian supplier. Consider qualifying a second source.
§6.2 Single-source lock-in by country
United States 2 single-source buyers
| Importer | Current supplier | USD | Unit $ | Dosage |
|---|---|---|---|---|
| ZYDUS PHARMACEUTICALS … | ZYDUS LIFESCIENCES LTD | $378K | $0.041 | Tablet |
| J. KNIPPER & COMPANY | ALEMBIC PHARMACEUTIC… | $11K | $0.017 | Tablet |
Germany 2 single-source buyers
| Importer | Current supplier | USD | Unit $ | Dosage |
|---|---|---|---|---|
| STADAPHARM GMBH | ALEMBIC PHARMACEUTIC… | $222K | $0.088 | Tablet |
| ALIUD PHARMA GMBH | ALEMBIC PHARMACEUTIC… | $37K | $0.078 | Tablet |
Sri Lanka 2 single-source buyers
| Importer | Current supplier | USD | Unit $ | Dosage |
|---|---|---|---|---|
| HATTON NATIONAL BANK PLC | TORRENT PHARMACEUTIC… | $85K | $35.129 | Tablet |
| HEMAS PHARMACEUTICALS … | USV PVT LTD | $8K | $2.550 | Tablet |
Kenya 2 single-source buyers
| Importer | Current supplier | USD | Unit $ | Dosage |
|---|---|---|---|---|
| MEDOX PHARMACEUTICALS … | TORRENT PHARMACEUTIC… | $5K | $8.537 | Tablet |
| SALAMA PHARMACUTICALS … | M T MADON EXPORTS | $126.944 | $0.254 | Tablet |
United Arab Emirates 2 single-source buyers
| Importer | Current supplier | USD | Unit $ | Dosage |
|---|---|---|---|---|
| EMIRATES POST COMPANY | DERRIC WOOD | $161.717 | $2.450 | Tablet |
| ARROW TRADING FZE | BAKER & DAVIS PVT LTD | $139.170 | $0.139 | Tablet |
§6.3 Price positioning — top 25 importers
| # | Importer | Country | USD | $/ship | Tier |
|---|---|---|---|---|---|
| 1 | ZYDUS PHARMACEUTICAL… | United States | $378K | $47K | Premium |
| 2 | STADAPHARM GMBH | Germany | $222K | $28K | Mid |
| 3 | NEOETHICALS CIA LTDA… | Ecuador | $194K | $194K | Premium |
| 4 | TILLOMED LABORATORIE… | United Kingdom | $135K | $45K | Premium |
| 5 | JDS CO LTD | Myanmar | $105K | $105K | Premium |
| 6 | HATTON NATIONAL BANK… | Sri Lanka | $85K | $85K | Premium |
| 7 | FE BARAKA DORI FARM … | Uzbekistan | $75K | $75K | Premium |
| 8 | EMCURE PHARMA CHILE … | Chile | $51K | $51K | Premium |
| 9 | PHARMACHEM PVT LTD | Nepal | $47K | $7K | Budget |
| 10 | J.D.S CO LTD | Myanmar | $43K | $9K | Budget |
| 11 | ROPACK | Canada | $42K | $42K | Premium |
| 12 | ALIUD PHARMA GMBH | Germany | $37K | $7K | Budget |
| 13 | ALLOGA (NEDERLAND) B… | Netherlands | $33K | $11K | Budget |
| 14 | J. KNIPPER & COMPANY | United States | $11K | $11K | Budget |
| 15 | ESRAR PHARMA | Yemen | $10K | $10K | Budget |
| 16 | LLP DARI-PHARM (KAZA… | Kazakhstan | $10K | $10K | Budget |
| 17 | HEMAS PHARMACEUTICAL… | Sri Lanka | $8K | $8K | Budget |
| 18 | ROYAL DISTRIBUTION C… | Thailand | $7K | $7K | Budget |
| 19 | GLADPHARM LTD | Ukraine | $6K | $6K | Budget |
| 20 | NOMECO HEALTHCARE LO… | Denmark | $5K | $5K | Budget |
| 21 | MEDOX PHARMACEUTICAL… | Kenya | $5K | $5K | Budget |
| 22 | CSP COURNON | France | $4K | $4K | Budget |
| 23 | TSAMPAKA PHARMACEUTI… | Bhutan | $3K | $3K | Budget |
| 24 | PHARMACEUTICAL AND C… | Zimbabwe | $1K | $1K | Budget |
| 25 | ETEMAD MOSLEH LTD | Afghanistan | $688.016 | $688.000 | Budget |
06
PART III — WHO’S IN THIS MARKET
Market Relationship Map
The top 20 × 20 supplier ↔ buyer network as a circular flow diagram
Fig 6.3 ZYDUS LIFESCIENCES LTD → ZYDUS PHARMACEUTICALS USA INC is the strongest relationship.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Left semicircle = top 20 Indian suppliers; right = top 20 global buyers. Arc length = total USD; colored ribbons = individual relationships, thickness = USD value. Insight: follow the thickest ribbons to identify the dominant trading pairs.
07
PART IV — MARKET BEHAVIOR
Price Benchmarks & Analysis
How Indian leflunomide prices vary by supplier, country and dosage form
KEY TAKEAWAY
Leflunomide prices span 27415× ($0.0013 → $35.13). The coefficient of variation is 2.37. Dosage form, not destination, is the primary price driver.
S FOR SUPPLIERS
Use the box plot to see where your product sits on the price spectrum. The tornado chart shows exactly where you sit relative to the market median.
B FOR BUYERS
Use this section to benchmark the price you pay against the market. The percentile strip tells you if your current supplier is charging you premium, mid-market or budget rates.
§7.1 Price distribution · Table 7.1
| Statistic | Value | Interpretation |
|---|---|---|
| Min | $0.0013 | Lowest observed unit price |
| P5 | $0.027 | 5th percentile |
| P25 | $0.070 | 25th percentile (Q1) |
| Median | $0.288 | 50th percentile (Q2) |
| P75 | $2.52 | 75th percentile (Q3) |
| P95 | $8.54 | 95th percentile |
| Max | $35.13 | Highest observed unit price |
| Mean | $2.31 | Arithmetic average |
| CV | 237% | Coefficient of variation (std/mean) |
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
Fig 7.1 ANH PHARMACEUTICALS PVT LTD prices at $24.52/unit vs market median $0.288.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Each bar shows one supplier’s average unit price relative to the market median (dashed line). Red = above median (premium), green = below (budget).
COMMODITY KINGS
high volume · low unit price
Bulk API/tablet. Largest absolute USD despite lowest per-unit prices. e.g. ZYDUS LIFESCIENCES LTD Sourcing: best for cost-driven procurement.
BULK LEADERS
high volume · premium price
Branded-generic leaders, above-median pricing. e.g. TORRENT PHARMACEUTICALS LTD Sourcing: hardest to displace; compete on relationship.
LONG-TAIL
low volume · low unit price
Spot/opportunistic players. e.g. CAPLIN POINT LABORATORIES Sourcing: first to approach for new tenders.
PREMIUM NICHE
low volume · premium price
Sterile injectables and infusions. Hospital-grade. e.g. ASPO PHARMACEUTICALS LLP Sourcing: expect 10× price vs tablet.
07
PART IV — MARKET BEHAVIOR
Price Benchmarks & Analysis
Outlier forensics and the procurement cheat sheet — what to expect to pay by country × dosage
KEY TAKEAWAY
Extreme prices are real: the highest are specialty/sterile formulations; the lowest are bulk API. The cheat sheet matrix is the take-home reference for procurement teams.
§7.2 Outlier forensics — top 10 highest and 10 lowest unit prices
↑ TOP 10 HIGHEST USD/UNIT
| Date | Exporter | Country | Dosage | Qty | USD | $/unit | Why |
|---|---|---|---|---|---|---|---|
| Dec 2025 | TORRENT PHARMACE… | Sri Lanka | Tablet | 2K | $85K | $35.13 | Specialty / small-batch |
| Dec 2025 | ANH PHARMACEUTIC… | Guatemala | Tablet | 486 | $12K | $24.52 | Specialty / small-batch |
| Dec 2025 | ANH PHARMACEUTIC… | Guatemala | Tablet | 486 | $12K | $24.52 | Specialty / small-batch |
| Nov 2025 | TORRENT PHARMACE… | Myanmar | Tablet | 10K | $105K | $10.29 | Specialty / small-batch |
| Dec 2025 | TORRENT PHARMACE… | Kenya | Tablet | 536 | $5K | $8.54 | Specialty / small-batch |
| Oct 2025 | KUSUM HEALTHCARE… | Myanmar | Tablet | 929 | $5K | $5.06 | Specialty / small-batch |
| Nov 2025 | KUSUM HEALTHCARE… | Myanmar | Tablet | 4K | $19K | $4.83 | Specialty / small-batch |
| Nov 2025 | KUSUM HEALTHCARE… | Myanmar | Tablet | 4K | $19K | $4.83 | Specialty / small-batch |
| Oct 2025 | KUSUM HEALTHCARE… | Ukraine | Tablet | 1K | $6K | $4.04 | Specialty / small-batch |
| Dec 2025 | ARIHANT EXPORTERS | Papua New Guinea | Tablet | 80 | $276.76 | $3.46 | Specialty / small-batch |
↓ TOP 10 LOWEST USD/UNIT
| Date | Exporter | Country | Dosage | Qty | USD | $/unit | Why |
|---|---|---|---|---|---|---|---|
| Dec 2025 | IPCA LABORATORIE… | Myanmar | Tablet | 48K | $61.51 | $0.0013 | Bulk generic tablet |
| Nov 2025 | DEVLIFE CORP PVT… | Bhutan | Tablet | 220K | $3K | $0.014 | |
| Dec 2025 | MDS ENTERPRISES | United Arab Emirates | Tablet | 20 | $0.319 | $0.016 | Small sample / trial shipment |
| Oct 2025 | ALEMBIC PHARMACE… | United States | Tablet | 668K | $11K | $0.017 | |
| Dec 2025 | MDS ENTERPRISES | United Arab Emirates | Tablet | 20 | $0.547 | $0.027 | Small sample / trial shipment |
| Nov 2025 | ZYDUS LIFESCIENC… | United States | Tablet | 161K | $5K | $0.034 | |
| Nov 2025 | ZYDUS LIFESCIENC… | United States | Tablet | 1.3M | $45K | $0.034 | Bulk volume discount |
| Oct 2025 | ZYDUS LIFESCIENC… | United States | Tablet | 1.3M | $46K | $0.035 | Bulk volume discount |
| Dec 2025 | ZYDUS LIFESCIENC… | United States | Tablet | 434K | $15K | $0.035 | |
| Nov 2025 | ZYDUS LIFESCIENC… | United States | Tablet | 285K | $10K | $0.035 |
§7.3 Procurement cheat sheet — median USD/unit by country × dosage
Fig 7.2 Median unit price by country × dosage form — darker cells = higher prices.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Each cell shows the median price per unit for that country-dosage combination. Dark blue = expensive, light = cheap. Blank cells = no shipments in that combination.
NEGOTIATION RANGE
Use each cell value as the anchor price. Typical dynamics:
- Budget buyer: anchor − 10–15% (floor = cost + freight)
- Mid-market: anchor ± 5–10%
- Premium/tender: anchor + 10–25% (regulated, quality premium)
- Injection/infusion: always 4–10× the tablet price
KEY TAKEAWAYS
- Dosage form is the #1 price driver, not destination
- Light cells = easy-entry markets for small suppliers
- Dark cells = premium markets requiring regulatory investment
08
PART IV — MARKET BEHAVIOR
Shipping Ports & Trade Routes
Which Indian ports ship leflunomide, which global ports receive it, and which corridors are high-value vs bulk
KEY TAKEAWAY
Leflunomide leaves India through 11+ ports. The top 5 (NHAVA SHEVA SEA (JNPT), DELHI AIR, MUNDRA SEA) handle 92.5% of total USD. SEA moves 36% of shipments.
S FOR SUPPLIERS
Use the dumbbell to classify your port as high-value hub or bulk workhorse. Note the short-sea routes — Bangladesh, Sri Lanka, Myanmar and East Africa are the easiest logistics corridors for first-time exporters.
B FOR BUYERS
Use the destination port ranking to find which Indian ports serve your market. The lead-time estimates tell you what transit time to expect.
Fig 8.1 NHAVA SHEVA SEA (JNPT) handles $461K — top 11 Indian origin ports by trade value.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Each bar = one Indian port. Bar length = USD value. The largest ports handle the majority of trade.
Fig 8.2 Savannah is the #1 global destination port — top 25 by USD value.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Each bar = one destination port worldwide. Bar length = USD value received from India.
§8.1 Reference transit times for key India → global corridors
| Route | Mode | Transit time | Notes |
|---|---|---|---|
| NHAVA SHEVA SEA (JNPT) → US East Coast | Sea | 22–28 days | Via Suez; 2–3 transshipments typical |
| NHAVA SHEVA SEA (JNPT) → Lagos (Nigeria) | Sea | 18–24 days | Direct liner service available |
| MUMBAI AIR (SAHAR) → New York JFK | Air | 3–5 days | Direct cargo; cold-chain available |
| MUNDRA SEA → Rotterdam | Sea | 20–26 days | Via Suez; Hamburg also served |
| HYDERABAD AIR → London Heathrow | Air | 2–4 days | Pharma-grade cargo corridor |
| CHENNAI SEA → Chittagong (Bangladesh) | Sea | 7–12 days | Short-sea route; high frequency |
| RAXAUL → Birgunj (Nepal) | Road | 1–2 days | Land border crossing |
| NHAVA SHEVA SEA (JNPT) → Mombasa (Kenya) | Sea | 14–20 days | Direct or via Colombo hub |
Table 8.1 — Reference times based on standard shipping corridors. Air = 2–5 days; sea = 7–28 days; road = 1–2 days. Add 3–7 days for customs clearance at destination.
08
PART IV — MARKET BEHAVIOR
Shipping Ports & Trade Routes
Trade corridors — origin port to mode of transport to destination region
KEY TAKEAWAY
SEA dominates at 36% of shipments. The alluvial traces every dollar from Indian origin port through transport mode to destination region.
SEA
$763K
47.9% of USD · 35.7% of ships
AIR
$718K
45.1% of USD · 50.0% of ships
ICD
$62K
3.9% of USD · 4.8% of ships
ROAD
$50K
3.2% of USD · 9.5% of ships
Fig 8.3 The dominant corridor is NHAVA SHEVA SEA (JNPT) → Sea → Europe ($285K).
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Left = Indian origin ports. Middle = transport mode. Right = destination region. Ribbon thickness = USD value; color = mode. Follow the thickest ribbons to find the highest-value corridors.
09
PART V — ACTION
Strategic Opportunities & Action Plan
Market concentration, supply-chain risk, and the dependency patterns that signal where to act
KEY TAKEAWAY
Germany is the most concentrated destination (HHI 10000, 1 suppliers). United Arab Emirates is the most competitive (HHI 5058).
S FOR SUPPLIERS
The HHI barbell shows where competitors have locked up a market (concentrated = poaching opportunity) vs where you must compete on quality (fragmented). The slope chart reveals who is gaining ground.
B FOR BUYERS
The HHI barbell tells you whether your country has enough supplier options. If concentrated (red zone), you have fewer alternatives.
Fig 9.1 Germany (HHI 10,000) is the most concentrated — United Arab Emirates (HHI 5,058) is the most competitive.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
What is HHI? The Herfindahl-Hirschman Index measures how concentrated a market is among its suppliers. It ranges from 0 to 10,000. Below 1,500 (green zone) = many suppliers compete openly — healthy, competitive market with low risk. 1,500–2,500 (yellow zone) = a few suppliers hold significant share — moderate concentration. Above 2,500 (red zone) = one or two suppliers dominate the market — high risk for buyers who may lose supply, and hard to break into for new suppliers. Conclusion: 20 of 20 destination markets are concentrated (red zone). 0 are competitive (green zone). Buyers in red-zone markets should urgently qualify a second Indian supplier to reduce dependency risk.
§9.1 Single-source dependencies
| Buyer | Country | Sole supplier | USD | Ships | Risk |
|---|---|---|---|---|---|
| ZYDUS PHARMACEUTICAL… | United States | ZYDUS LIFESCIENC… | $378K | 8 | HIGH |
| STADAPHARM GMBH | Germany | ALEMBIC PHARMACE… | $222K | 8 | HIGH |
| NEOETHICALS CIA LTDA… | Ecuador | CAPLIN POINT LAB… | $194K | 1 | HIGH |
| TILLOMED LABORATORIE… | United Kingdom | EMCURE PHARMACEU… | $135K | 3 | HIGH |
| JDS CO LTD | Myanmar | TORRENT PHARMACE… | $105K | 1 | HIGH |
| HATTON NATIONAL BANK… | Sri Lanka | TORRENT PHARMACE… | $85K | 1 | MEDIUM |
| FE BARAKA DORI FARM … | Uzbekistan | KUSUM HEALTHCARE… | $75K | 1 | MEDIUM |
| EMCURE PHARMA CHILE … | Chile | EMCURE PHARMACEU… | $51K | 1 | MEDIUM |
Conclusion: 29 buyers depend on exactly one Indian supplier, representing $1.5M in trade. For suppliers: each row is a competitor’s locked-in customer you can target.
§9.2 Multi-source resilience
| Buyer | Country | Suppliers | USD | Dominant | Resilience |
|---|
Conclusion: 0 of these buyers have HIGH resilience (3+ active suppliers). These are the hardest accounts to win but safest partners for long-term contracts.
09
PART V — ACTION
Strategic Opportunities & Action Plan
Market entry playbook and risk landscape by destination country
KEY TAKEAWAY
15 target markets with specific entry approaches. Large suppliers: focus on regulated Tier 1 markets. Small/mid-size: start with Tier 2–3 (low barrier, growing demand).
§9.3 Sourcing recommendations · Table 9.1
| Country | Tier | Lead | Price | Risk | Entry approach |
|---|---|---|---|---|---|
| United States | Tier 3 (emerging) | 3–5 days (air) | $0.01–$0.10/unit | LOW | First-mover advantage |
| Germany | Tier 3 (emerging) | 3–5 days (air) | $0.01–$0.10/unit | LOW | First-mover advantage |
| Ecuador | Tier 3 (emerging) | 3–5 days (air) | $0.10–$1/unit | LOW | First-mover advantage |
| Myanmar | Tier 3 (emerging) | 3–5 days (air) | $1–$10/unit | LOW | First-mover advantage |
| United Kingdom | Tier 3 (emerging) | 14–28 days (sea) | $1–$10/unit | LOW | First-mover advantage |
| Sri Lanka | Tier 3 (emerging) | 3–5 days (air) | $1–$10/unit | LOW | First-mover advantage |
| Uzbekistan | Tier 3 (emerging) | 14–28 days (sea) | $1–$10/unit | LOW | First-mover advantage |
| Chile | Tier 3 (emerging) | 14–28 days (sea) | $1–$10/unit | LOW | First-mover advantage |
| Nepal | Tier 3 (emerging) | 14–28 days (sea) | $1–$10/unit | LOW | First-mover advantage |
| Canada | Tier 3 (emerging) | 3–5 days (air) | $0.10–$1/unit | LOW | First-mover advantage |
| Netherlands | Tier 3 (emerging) | 14–28 days (sea) | $0.01–$0.10/unit | LOW | First-mover advantage |
| Guatemala | Tier 3 (emerging) | 14–28 days (sea) | $1–$10/unit | LOW | First-mover advantage |
| Yemen | Tier 3 (emerging) | 14–28 days (sea) | $0.10–$1/unit | LOW | First-mover advantage |
| Kazakhstan | Tier 3 (emerging) | 14–28 days (sea) | $1–$10/unit | LOW | First-mover advantage |
| Venezuela | Tier 3 (emerging) | 3–5 days (air) | $0.10–$1/unit | LOW | First-mover advantage |
For suppliers: Tier 1 markets (US, UK, France) require regulatory investment but offer premium pricing. Tier 3 markets (emerging) have low barriers — ideal for first-time exporters. For buyers: Use the price band and lead time to benchmark your current supplier’s terms.
Fig 9.2 0 markets in the Growth Opportunity zone (competitive + growing). 13 in Fragile Dependency (concentrated + shrinking).
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Each bubble = one destination. X-axis = HHI (concentration). Y-axis = growth %. Bubble size = USD. Green zone (top-left) = Growth Opportunity — competitive markets that are growing, best for new entrants. Red zone (bottom-right) = Fragile Dependency — concentrated + shrinking, high supply-chain risk. Conclusion: Key markets are the top growth opportunities.
09
PART V — ACTION
Action Plan & Easy-Entry Markets
12 prioritised actions + 15 low-competition destination countries for small & mid-size suppliers
KEY TAKEAWAY
Quick Wins: execute this quarter. Big Bets: plan for next 6–12 months. Plus 15 countries with ≤5 Indian suppliers — the best entry points for SMEs.
S
FOR SUPPLIERS
| ID | Action | Timing | Impact |
|---|---|---|---|
| A1 | Pitch top single-source buyer in United States | This Q | HIGH |
| A2 | Offer alternative to top multi-source buyer | This Q | HIGH |
| A3 | Audit Germany lock-ins (HHI 10000) | This Q | MED |
| A5 | Enter Sri Lanka (2 suppliers) | This Q | HIGH |
| A6 | Enter United States (2 suppliers) | This Q | MED |
| A8 | Build Germany distribution | 6–12m | HIGH |
| A9 | Bundle injection/infusion catalog for premium markets | 6–12m | MED |
B
FOR BUYERS
| ID | Action | Timing | Impact |
|---|---|---|---|
| A4 | Monitor rising exporters (TORRENT PHARMACEUTICALS) | This Q | MED |
| A7 | Register for United States tenders | 6–12m | HIGH |
| A10 | Track quarterly HHI shifts across key destinations | This Q | LOW |
| A11 | Map competitor buyer portfolios quarterly | This Q | MED |
| A12 | Qualify second source for single-source buyers | This Q | MED |
§9.4 Easy-entry markets — 15 countries with ≤5 Indian suppliers
| # | Country | Region | Suppliers | Q4 USD | Growth | Barrier | Why this is easy |
|---|---|---|---|---|---|---|---|
| 1 | Sri Lanka | Asia | 2 | $93K | +1010.2% | LOW | Only 2 Indian suppliers — near-monopoly, easy second-source entry |
| 2 | United States | Other | 2 | $433K | -73.2% | LOW | Only 2 Indian suppliers — near-monopoly, easy second-source entry |
| 3 | Germany | Other | 1 | $259K | -100% | LOW | Only 1 Indian suppliers — near-monopoly, easy second-source entry |
| 4 | Ecuador | Other | 1 | $194K | 0% | LOW | Only 1 Indian suppliers — near-monopoly, easy second-source entry |
| 5 | United Kingdom | Other | 1 | $135K | +40.9% | LOW | Only 1 Indian suppliers — near-monopoly, easy second-source entry |
| 6 | Myanmar | Asia | 3 | $148K | -98.7% | LOW | Low competition (3 suppliers), accessible market |
| 7 | Uzbekistan | Asia | 1 | $75K | -100% | LOW | Only 1 Indian suppliers — near-monopoly, easy second-source entry |
| 8 | Chile | Other | 1 | $51K | 0% | LOW | Only 1 Indian suppliers — near-monopoly, easy second-source entry |
| 9 | Nepal | Asia | 1 | $47K | 0% | LOW | Only 1 Indian suppliers — near-monopoly, easy second-source entry |
| 10 | Canada | Other | 1 | $42K | 0% | LOW | Only 1 Indian suppliers — near-monopoly, easy second-source entry |
| 11 | Netherlands | Other | 1 | $33K | -100% | LOW | Only 1 Indian suppliers — near-monopoly, easy second-source entry |
| 12 | Guatemala | Other | 1 | $24K | 0% | LOW | Only 1 Indian suppliers — near-monopoly, easy second-source entry |
| 13 | Yemen | Other | 1 | $10K | -100% | LOW | Only 1 Indian suppliers — near-monopoly, easy second-source entry |
| 14 | Kazakhstan | Asia | 1 | $10K | 0% | LOW | Only 1 Indian suppliers — near-monopoly, easy second-source entry |
| 15 | Venezuela | Other | 1 | $7K | -100% | LOW | Only 1 Indian suppliers — near-monopoly, easy second-source entry |
This report covers 84 2025-Q4 Leflunomide shipments.
TransData Nexus tracks 3.37M+ shipments across all pharmaceuticals since 2020.
→ transdatanexus.com/pharmaceutical/leflunomide
10
PART VI — EVIDENCE REGISTER
Comprehensive Shipment Records by Region
Authoritative source behind all analytics in this report — every shipment appears exactly once
KEY TAKEAWAY
This section contains every one of the 84 2025-Q4 leflunomide shipments, organised by Region → Exporter → Shipment rows. No row is duplicated.
S FOR SUPPLIERS
Jump to any destination country to see exactly who your competitors ship to, what they charge, through which port, and how often.
B FOR BUYERS
Jump to your country to see every Indian leflunomide shipment that arrived in 2025-Q4: supplier, price, dosage, port.
§10.1 Global totals
SHIPMENTS
84
across all regions
TOTAL USD
$1.59M
2025-Q4 FOB value
UNITS
15.6M
tablets, capsules, etc.
SUPPLIERS
21
Indian exporters
BUYERS
32
global importers
COUNTRIES
27
destinations
§10.2 Regional breakdown
§10.3 Key insights from the data
Africa is the largest region at $6K (0.4%), spanning 2 countries.
21 Indian suppliers shipped to 32 buyers across 27 countries — average shipment value $19K.
Top 0 markets: .
Every row below is real customs data — date, importer, dosage, brand, quantity, unit price, total USD, origin port, destination port, and transport mode.
§10.4 How to read a country page
1
6 KPI cards — shipments, USD, qty, exporters, importers, avg unit price.
2
4 mini-lists — top exporters, importers, dosages, monthly trend.
3
Shipment register — every row grouped by exporter. No row is duplicated or omitted.
10
PART VI — DRILL-DOWN · AFRICA
Region: Africa
2 countries · 3 shipments · $6K · 2 Indian suppliers · 3 buyers
SHIPMENTS
3
USD
$6K
COUNTRIES
2
SUPPLIERS
2
BUYERS
3
HHI
9,586
concentrated
Top 2 destination countries in Africa
1
Kenya (78.4%)
$5K
2
Zimbabwe (21.6%)
$1K
Top 2 Indian suppliers into Africa
1
TORRENT PHARMACEUTICALS LTD
$6K
2
M T MADON EXPORTS
$126.94
Top 3 Africa importers
1
MEDOX PHARMACEUTICALS LTD · Kenya
$5K
2
PHARMACEUTICAL AND CHEMICAL DISTRIB · Zimbabwe
$1K
3
SALAMA PHARMACUTICALS LTD · Kenya
$126.94
Top 1 dosage forms
1
Tablet
$6K
Monthly trend
| Month | Ships | USD | Avg/ship |
|---|---|---|---|
| Oct | 1 | $1K | $1K |
| Nov | 0 | $0.0000 | — |
| Dec | 2 | $5K | $2K |
Shipment register · 3 rows · grouped by exporter
| # | Date | Importer | Country | Dosage | Qty | Unit | Unit $ | Total $ | Origin | Dest | Mode |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SUPPLIER #1 — TORRENT PHARMACEUTICALS LTD · 2 shipments · $6K | |||||||||||
| 1 | Oct 2025 | PHARMACEUTICAL AND CHEMICAL DISTRIB | Zimbabwe | Tablet | 384 | NOS | $3.38 | $1K | NHAVA SHEVA SEA (JNPT) | Harare | SEA |
| 2 | Dec 2025 | MEDOX PHARMACEUTICALS LTD | Kenya | Tablet | 536 | NOS | $8.54 | $5K | MUMBAI AIR (SAHAR) | NAIROBI | AIR |
| SUPPLIER #2 — M T MADON EXPORTS · 1 shipments · $126.94 | |||||||||||
| 3 | Dec 2025 | SALAMA PHARMACUTICALS LTD | Kenya | Tablet | 500 | NOS | $0.254 | $126.94 | MUMBAI AIR (SAHAR) | NAIROBI | AIR |
10
PART VI — DRILL-DOWN · ASIA
Region: Asia
12 countries · 40 shipments · $393K · 12 Indian suppliers · 16 buyers
SHIPMENTS
40
USD
$393K
COUNTRIES
12
SUPPLIERS
12
BUYERS
16
HHI
4,703
concentrated
Top 12 destination countries in Asia
1
Myanmar (37.6%)
$148K
2
Sri Lanka (23.6%)
$93K
3
Uzbekistan (19.1%)
$75K
4
Nepal (12.0%)
$47K
5
Yemen (2.5%)
$10K
6
Kazakhstan (2.4%)
$10K
7
Thailand (1.7%)
$7K
8
Bhutan (0.8%)
$3K
9
Afghanistan (0.2%)
$688.02
10
United Arab Emirates (0.1%)
$371.64
11
Malaysia (0.0%)
$48.62
12
Maldives (0.0%)
$17.13
Top 12 Indian suppliers into Asia
1
TORRENT PHARMACEUTICALS LTD
$237K
2
KUSUM HEALTHCARE PVT LTD
$127K
3
ASPO PHARMACEUTICALS LLP
$10K
4
USV PVT LTD
$8K
5
AKRITI PHARMACEUTICALS PVT LTD
$7K
6
DEVLIFE CORP PVT LTD
$3K
7
BAKER & DAVIS PVT LTD
$897.07
8
DERRIC WOOD
$161.72
9
IPCA LABORATORIES LTD
$61.51
10
BABA AGENCIES
$48.62
11
VEA IMPEX (I) PVT LTD
$17.13
12
MDS ENTERPRISES
$0.866
Top 14 Asia importers
1
JDS CO LTD · Myanmar
$105K
2
HATTON NATIONAL BANK PLC · Sri Lanka
$85K
3
FE BARAKA DORI FARM LLC · Uzbekistan
$75K
4
PHARMACHEM PVT LTD · Nepal
$47K
5
J.D.S CO LTD · Myanmar
$43K
6
ESRAR PHARMA · Yemen
$10K
7
LLP DARI-PHARM (KAZAKHSTAN) · Kazakhstan
$10K
8
HEMAS PHARMACEUTICALS PVT LTD · Sri Lanka
$8K
9
ROYAL DISTRIBUTION CO LTD · Thailand
$7K
10
TSAMPAKA PHARMACEUTICAL & MEDICAL · Bhutan
$3K
11
ETEMAD MOSLEH LTD · Afghanistan
$688.02
12
EMIRATES POST COMPANY · United Arab Emirates
$161.72
13
ARROW TRADING FZE · United Arab Emirates
$139.17
14
VITAL RANK SDN BHD · Malaysia
$24.31
Top 1 dosage forms
1
Tablet
$393K
Monthly trend
| Month | Ships | USD | Avg/ship |
|---|---|---|---|
| Oct | 5 | $104K | $21K |
| Nov | 19 | $187K | $10K |
| Dec | 16 | $102K | $6K |
Shipment register · 40 rows · grouped by exporter
| # | Date | Importer | Country | Dosage | Qty | Unit | Unit $ | Total $ | Origin | Dest | Mode |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SUPPLIER #1 — TORRENT PHARMACEUTICALS LTD · 9 shipments · $237K | |||||||||||
| 1 | Nov 2025 | PHARMACHEM PVT LTD | Nepal | Tablet | 1.0K | NOS | $1.29 | $1K | RAXAUL | Birgunj | ROAD |
| 2 | Nov 2025 | PHARMACHEM PVT LTD | Nepal | Tablet | 1.0K | NOS | $2.29 | $2K | RAXAUL | Birgunj | ROAD |
| 3 | Nov 2025 | PHARMACHEM PVT LTD | Nepal | Tablet | 5.0K | NOS | $1.29 | $6K | RAXAUL | Birgunj | ROAD |
| 4 | Nov 2025 | PHARMACHEM PVT LTD | Nepal | Tablet | 9.0K | NOS | $2.29 | $21K | RAXAUL | Birgunj | ROAD |
| 5 | Nov 2025 | JDS CO LTD | Myanmar | Tablet | 10.2K | NOS | $10.29 | $105K | DELHI AIR | YANGON | AIR |
| 6 | Dec 2025 | PHARMACHEM PVT LTD | Nepal | Tablet | 2.0K | NOS | $1.29 | $3K | RAXAUL | BIRGUNJ | ROAD |
| 7 | Dec 2025 | PHARMACHEM PVT LTD | Nepal | Tablet | 3.0K | NOS | $2.52 | $8K | RAXAUL | BIRGUNJ | ROAD |
| 8 | Dec 2025 | PHARMACHEM PVT LTD | Nepal | Tablet | 5.0K | NOS | $1.29 | $6K | RAXAUL | BIRGUNJ | ROAD |
| 9 | Dec 2025 | HATTON NATIONAL BANK PLC | Sri Lanka | Tablet | 2.4K | NOS | $35.13 | $85K | DELHI AIR | COLOMBO | AIR |
| SUPPLIER #2 — KUSUM HEALTHCARE PVT LTD · 5 shipments · $127K | |||||||||||
| 10 | Oct 2025 | J.D.S CO LTD | Myanmar | Tablet | 929 | NOS | $5.06 | $5K | TUGHLAKABAD ICD | Yangon | ICD |
| 11 | Oct 2025 | FE BARAKA DORI FARM LLC | Uzbekistan | Tablet | 38.9K | NOS | $1.93 | $75K | NHAVA SHEVA SEA (JNPT) | Tashkent | SEA |
| 12 | Nov 2025 | LLP DARI-PHARM (KAZAKHSTAN) | Kazakhstan | Tablet | 4.9K | NOS | $1.95 | $10K | NHAVA SHEVA SEA (JNPT) | Almaty | SEA |
| 13 | Nov 2025 | J.D.S CO LTD | Myanmar | Tablet | 4.0K | NOS | $4.83 | $19K | DELHI AIR | YANGON | AIR |
| 14 | Nov 2025 | J.D.S CO LTD | Myanmar | Tablet | 4.0K | NOS | $4.83 | $19K | DELHI AIR | YANGON | AIR |
| SUPPLIER #3 — ASPO PHARMACEUTICALS LLP · 1 shipments · $10K | |||||||||||
| 15 | Oct 2025 | ESRAR PHARMA | Yemen | Tablet | 20.0K | PCS | $0.489 | $10K | MUNDRA SEA | ADEN | SEA |
| SUPPLIER #4 — USV PVT LTD · 1 shipments · $8K | |||||||||||
| 16 | Oct 2025 | HEMAS PHARMACEUTICALS PVT LTD | Sri Lanka | Tablet | 3.0K | NOS | $2.55 | $8K | NHAVA SHEVA SEA (JNPT) | Colombo | SEA |
| SUPPLIER #5 — AKRITI PHARMACEUTICALS PVT LTD · 1 shipments · $7K | |||||||||||
| 17 | Oct 2025 | ROYAL DISTRIBUTION CO LTD | Thailand | Tablet | 5.0K | NOS | $1.37 | $7K | NHAVA SHEVA SEA (JNPT) | Yangon | SEA |
| SUPPLIER #6 — DEVLIFE CORP PVT LTD · 1 shipments · $3K | |||||||||||
| 18 | Nov 2025 | TSAMPAKA PHARMACEUTICAL & MEDICAL | Bhutan | Tablet | 219.8K | NOS | $0.014 | $3K | JAIGAON LCS | Phuntsholing | ROAD |
| SUPPLIER #7 — BAKER & DAVIS PVT LTD · 4 shipments · $897.07 | |||||||||||
| 19 | Nov 2025 | ARROW TRADING FZE | United Arab Emirates | Tablet | 500 | NOS | $0.139 | $69.29 | MUMBAI AIR (SAHAR) | DUBAI | AIR |
| 20 | Nov 2025 | ARROW TRADING FZE | United Arab Emirates | Tablet | 500 | NOS | $0.140 | $69.88 | MUMBAI AIR (SAHAR) | DUBAI | AIR |
| 21 | Nov 2025 | UNKNOWN BUYER | United Arab Emirates | Tablet | 500 | NOS | $0.140 | $69.88 | MUMBAI AIR (SAHAR) | DUBAI | AIR |
| 22 | Nov 2025 | ETEMAD MOSLEH LTD | Afghanistan | Tablet | 4.9K | NOS | $0.140 | $688.02 | DELHI AIR | KABUL | AIR |
| SUPPLIER #8 — DERRIC WOOD · 8 shipments · $161.72 | |||||||||||
| 23 | Nov 2025 | EMIRATES POST COMPANY | United Arab Emirates | Tablet | 9 | PCS | $2.74 | $24.63 | DELHI AIR | DUBAI | AIR |
| 24 | Nov 2025 | EMIRATES POST COMPANY | United Arab Emirates | Tablet | 9 | PCS | $2.73 | $24.60 | DELHI AIR | DUBAI | AIR |
| 25 | Nov 2025 | EMIRATES POST COMPANY | United Arab Emirates | Tablet | 9 | PCS | $1.62 | $14.56 | DELHI AIR | DUBAI | AIR |
| 26 | Nov 2025 | EMIRATES POST COMPANY | United Arab Emirates | Tablet | 9 | PCS | $1.63 | $14.66 | DELHI AIR | DUBAI | AIR |
| 27 | Dec 2025 | EMIRATES POST COMPANY | United Arab Emirates | Tablet | 6 | PCS | $2.76 | $16.54 | DELHI AIR | DUBAI | AIR |
| 28 | Dec 2025 | EMIRATES POST COMPANY | United Arab Emirates | Tablet | 6 | PCS | $2.83 | $16.99 | DELHI AIR | DUBAI | AIR |
| 29 | Dec 2025 | EMIRATES POST COMPANY | United Arab Emirates | Tablet | 6 | PCS | $2.75 | $16.53 | DELHI AIR | DUBAI | AIR |
| 30 | Dec 2025 | EMIRATES POST COMPANY | United Arab Emirates | Tablet | 12 | PCS | $2.77 | $33.21 | DELHI AIR | DUBAI | AIR |
| SUPPLIER #9 — IPCA LABORATORIES LTD · 2 shipments · $61.51 | |||||||||||
| 31 | Dec 2025 | J.D.S CO LTD | Myanmar | Tablet | 48.0K | TBS | $0.0000 | $0.0000 | MUMBAI AIR (SAHAR) | YANGON | SEA |
| 32 | Dec 2025 | J.D.S CO LTD | Myanmar | Tablet | 48.0K | TBS | $0.0013 | $61.51 | MUMBAI AIR (SAHAR) | YANGON | AIR |
| SUPPLIER #10 — BABA AGENCIES · 2 shipments · $48.62 | |||||||||||
| 33 | Nov 2025 | VITAL RANK SDN BHD | Malaysia | Tablet | 50 | NOS | $0.486 | $24.31 | CHENNAI AIR | KUALA LUMPUR - INT'L | AIR |
| 34 | Nov 2025 | UNKNOWN BUYER | Malaysia | Tablet | 50 | NOS | $0.486 | $24.31 | CHENNAI AIR | KUALA LUMPUR - INT'L | AIR |
| SUPPLIER #11 — VEA IMPEX (I) PVT LTD · 2 shipments · $17.13 | |||||||||||
| 35 | Dec 2025 | UNLISTED BUYER | Maldives | Tablet | 360 | NOS | $0.041 | $14.69 | MUMBAI AIR (SAHAR) | MALE | AIR |
| 36 | Dec 2025 | UNLISTED BUYER | Maldives | Tablet | 60 | NOS | $0.041 | $2.45 | MUMBAI AIR (SAHAR) | MALE | AIR |
| SUPPLIER #12 — MDS ENTERPRISES · 4 shipments · $0.866 | |||||||||||
| 37 | Dec 2025 | UNLISTED BUYER | United Arab Emirates | Tablet | 20 | NOS | $0.0000 | $0.0000 | MUMBAI AIR (SAHAR) | DUBAI | AIR |
| 38 | Dec 2025 | UNLISTED BUYER | United Arab Emirates | Tablet | 20 | NOS | $0.0000 | $0.0000 | MUMBAI AIR (SAHAR) | DUBAI | AIR |
| 39 | Dec 2025 | UNLISTED BUYER | United Arab Emirates | Tablet | 20 | NOS | $0.016 | $0.319 | MUMBAI AIR (SAHAR) | SHARJAH | AIR |
| 40 | Dec 2025 | UNLISTED BUYER | United Arab Emirates | Tablet | 20 | NOS | $0.027 | $0.547 | MUMBAI AIR (SAHAR) | SHARJAH | AIR |
10
PART VI — DRILL-DOWN · EUROPE
Region: Europe
6 countries · 22 shipments · $443K · 3 Indian suppliers · 7 buyers
SHIPMENTS
22
USD
$443K
COUNTRIES
6
SUPPLIERS
3
BUYERS
7
HHI
5,573
concentrated
Top 6 destination countries in Europe
1
Germany (58.6%)
$259K
2
United Kingdom (30.6%)
$135K
3
Netherlands (7.5%)
$33K
4
Ukraine (1.3%)
$6K
5
Denmark (1.2%)
$5K
6
France (0.8%)
$4K
Top 3 Indian suppliers into Europe
1
ALEMBIC PHARMACEUTICALS LTD
$301K
2
EMCURE PHARMACEUTICALS LTD
$135K
3
KUSUM HEALTHCARE PVT LTD
$6K
Top 7 Europe importers
1
STADAPHARM GMBH · Germany
$222K
2
TILLOMED LABORATORIES LTD · United Kingdom
$135K
3
ALIUD PHARMA GMBH · Germany
$37K
4
ALLOGA (NEDERLAND) B.VP.A. JAN DE R · Netherlands
$33K
5
GLADPHARM LTD · Ukraine
$6K
6
NOMECO HEALTHCARE LOGISTICS · Denmark
$5K
7
CSP COURNON · France
$4K
Top 2 dosage forms
1
Tablet
$431K
2
filmtablets
$12K
Monthly trend
| Month | Ships | USD | Avg/ship |
|---|---|---|---|
| Oct | 8 | $169K | $21K |
| Nov | 13 | $206K | $16K |
| Dec | 1 | $68K | $68K |
Shipment register · 22 rows · grouped by exporter
| # | Date | Importer | Country | Dosage | Qty | Unit | Unit $ | Total $ | Origin | Dest | Mode |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SUPPLIER #1 — ALEMBIC PHARMACEUTICALS LTD · 18 shipments · $301K | |||||||||||
| 1 | Oct 2025 | ALLOGA (NEDERLAND) B.VP.A. JAN DE R | Netherlands | Tablet | 88.2K | NOS | $0.089 | $8K | NHAVA SHEVA SEA (JNPT) | Hamburg | SEA |
| 2 | Oct 2025 | ALLOGA (NEDERLAND) B.VP.A. JAN DE R | Netherlands | Tablet | 290.9K | NOS | $0.061 | $18K | NHAVA SHEVA SEA (JNPT) | Hamburg | SEA |
| 3 | Oct 2025 | STADAPHARM GMBH | Germany | Tablet | 734.3K | NOS | $0.098 | $72K | NHAVA SHEVA SEA (JNPT) | Hamburg | SEA |
| 4 | Oct 2025 | ALLOGA (NEDERLAND) B.VP.A. JAN DE R | Netherlands | Tablet | 87.1K | NOS | $0.089 | $8K | NHAVA SHEVA SEA (JNPT) | Hamburg | SEA |
| 5 | Oct 2025 | CSP COURNON | France | Tablet | 49.3K | NOS | $0.071 | $4K | MUNDRA SEA | Hamburg | SEA |
| 6 | Oct 2025 | NOMECO HEALTHCARE LOGISTICS | Denmark | Tablet | 49.8K | NOS | $0.106 | $5K | MUNDRA SEA | Hamburg | SEA |
| 7 | Nov 2025 | ALIUD PHARMA GMBH | Germany | Tablet | 128.4K | NOS | $0.100 | $13K | MUMBAI AIR (SAHAR) | FRANKFURT/MAIN INT'L | AIR |
| 8 | Nov 2025 | STADAPHARM GMBH | Germany | Tablet | 547.5K | NOS | $0.098 | $53K | MUMBAI AIR (SAHAR) | FRANKFURT/MAIN INT'L | AIR |
| 9 | Nov 2025 | STADAPHARM GMBH | Germany | Tablet | 184.9K | NOS | $0.098 | $18K | MUMBAI AIR (SAHAR) | FRANKFURT/MAIN INT'L | AIR |
| 10 | Nov 2025 | STADAPHARM GMBH | Germany | Tablet | 100.5K | NOS | $0.071 | $7K | NHAVA SHEVA SEA (JNPT) | Hamburg | SEA |
| 11 | Nov 2025 | STADAPHARM GMBH | Germany | Tablet | 408.9K | NOS | $0.070 | $29K | NHAVA SHEVA SEA (JNPT) | Hamburg | SEA |
| 12 | Nov 2025 | STADAPHARM GMBH | Germany | Tablet | 82.6K | NOS | $0.099 | $8K | NHAVA SHEVA SEA (JNPT) | Hamburg | SEA |
| 13 | Nov 2025 | ALIUD PHARMA GMBH | Germany | Tablet | 18.4K | NOS | $0.071 | $1K | MUMBAI AIR (SAHAR) | FRANKFURT/MAIN INT'L | AIR |
| 14 | Nov 2025 | ALIUD PHARMA GMBH | Germany | Tablet | 153.2K | NOS | $0.070 | $11K | MUMBAI AIR (SAHAR) | FRANKFURT/MAIN INT'L | AIR |
| 15 | Nov 2025 | STADAPHARM GMBH | Germany | Tablet | 364.6K | NOS | $0.070 | $26K | MUMBAI AIR (SAHAR) | FRANKFURT/MAIN INT'L | AIR |
| 16 | Nov 2025 | STADAPHARM GMBH | Germany | Tablet | 93.6K | NOS | $0.098 | $9K | MUMBAI AIR (SAHAR) | FRANKFURT/MAIN INT'L | AIR |
| 17 | Nov 2025 | ALIUD PHARMA GMBH | Germany | filmtablets | 18.4K | NOS | $0.071 | $1K | MUMBAI AIR (SAHAR) | FRANKFURT/MAIN INT'L | AIR |
| 18 | Nov 2025 | ALIUD PHARMA GMBH | Germany | filmtablets | 153.2K | NOS | $0.070 | $11K | MUMBAI AIR (SAHAR) | FRANKFURT/MAIN INT'L | AIR |
| SUPPLIER #2 — EMCURE PHARMACEUTICALS LTD · 3 shipments · $135K | |||||||||||
| 19 | Oct 2025 | TILLOMED LABORATORIES LTD | United Kingdom | Tablet | 23.1K | NOS | $2.09 | $48K | NHAVA SHEVA SEA (JNPT) | Southampton | SEA |
| 20 | Nov 2025 | TILLOMED LABORATORIES LTD | United Kingdom | Tablet | 9.2K | NOS | $2.06 | $19K | NHAVA SHEVA SEA (JNPT) | Southampton | SEA |
| 21 | Dec 2025 | TILLOMED LABORATORIES LTD | United Kingdom | Tablet | 32.5K | NOS | $2.09 | $68K | NHAVA SHEVA SEA (JNPT) | Felixstowe | SEA |
| SUPPLIER #3 — KUSUM HEALTHCARE PVT LTD · 1 shipments · $6K | |||||||||||
| 22 | Oct 2025 | GLADPHARM LTD | Ukraine | Tablet | 1.5K | NOS | $4.04 | $6K | DADRI ICD | KOPER | ICD |
10
PART VI — DRILL-DOWN · AMERICAS
Region: Americas
6 countries · 16 shipments · $751K · 7 Indian suppliers · 7 buyers
SHIPMENTS
16
USD
$751K
COUNTRIES
6
SUPPLIERS
7
BUYERS
7
HHI
3,920
concentrated
Top 6 destination countries in Americas
1
United States (57.7%)
$433K
2
Ecuador (25.8%)
$194K
3
Chile (6.8%)
$51K
4
Canada (5.6%)
$42K
5
Guatemala (3.2%)
$24K
6
Venezuela (0.9%)
$7K
Top 7 Indian suppliers into Americas
1
ZYDUS LIFESCIENCES LTD
$422K
2
CAPLIN POINT LABORATORIES LTD
$194K
3
EMCURE PHARMACEUTICALS LTD
$51K
4
CIPLA LTD
$42K
5
ANH PHARMACEUTICALS PVT LTD
$24K
6
ALEMBIC PHARMACEUTICALS LTD
$11K
7
WESTCOAST PHARMACEUTICAL WORKS LTD
$7K
Top 5 Americas importers
1
ZYDUS PHARMACEUTICALS USA INC · United States
$378K
2
NEOETHICALS CIA LTDA DIRECCION · Ecuador
$194K
3
EMCURE PHARMA CHILE S.P.A · Chile
$51K
4
ROPACK · Canada
$42K
5
J. KNIPPER & COMPANY · United States
$11K
Top 1 dosage forms
1
Tablet
$751K
Monthly trend
| Month | Ships | USD | Avg/ship |
|---|---|---|---|
| Oct | 3 | $64K | $21K |
| Nov | 8 | $555K | $69K |
| Dec | 5 | $132K | $26K |
Shipment register · 16 rows · grouped by exporter
| # | Date | Importer | Country | Dosage | Qty | Unit | Unit $ | Total $ | Origin | Dest | Mode |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SUPPLIER #1 — ZYDUS LIFESCIENCES LTD · 9 shipments · $422K | |||||||||||
| 1 | Oct 2025 | ZYDUS PHARMACEUTICALS USA INC | United States | Tablet | 1.3M | NOS | $0.035 | $46K | DADRI ICD | SAVANNAH | ICD |
| 2 | Nov 2025 | ZYDUS PHARMACEUTICALS USA INC | United States | Tablet | 3.7M | NOS | $0.046 | $169K | MUNDRA SEA | Savannah | SEA |
| 3 | Nov 2025 | ZYDUS PHARMACEUTICALS USA INC | United States | Tablet | 928.1K | NOS | $0.046 | $42K | MUNDRA SEA | Savannah | SEA |
| 4 | Nov 2025 | ZYDUS PHARMACEUTICALS USA INC | United States | Tablet | 938.9K | NOS | $0.047 | $44K | DELHI AIR | MEMPHIS, TN | AIR |
| 5 | Nov 2025 | UNKNOWN BUYER | United States | Tablet | 938.9K | NOS | $0.047 | $44K | DELHI AIR | MEMPHIS, TN | AIR |
| 6 | Nov 2025 | ZYDUS PHARMACEUTICALS USA INC | United States | Tablet | 1.3M | NOS | $0.034 | $45K | MUNDRA SEA | Savannah | SEA |
| 7 | Nov 2025 | ZYDUS PHARMACEUTICALS USA INC | United States | Tablet | 160.6K | NOS | $0.034 | $5K | CMA CGM LOGISTICS ICD | SAVANNAH | ICD |
| 8 | Nov 2025 | ZYDUS PHARMACEUTICALS USA INC | United States | Tablet | 285.1K | NOS | $0.035 | $10K | DELHI AIR | MEMPHIS, TN | AIR |
| 9 | Dec 2025 | ZYDUS PHARMACEUTICALS USA INC | United States | Tablet | 434.2K | NOS | $0.035 | $15K | MUNDRA SEA | Savannah | SEA |
| SUPPLIER #2 — CAPLIN POINT LABORATORIES LTD · 1 shipments · $194K | |||||||||||
| 10 | Nov 2025 | NEOETHICALS CIA LTDA DIRECCION | Ecuador | Tablet | 673.3K | NOS | $0.288 | $194K | CHENNAI AIR | GUAYAQUIL | AIR |
| SUPPLIER #3 — EMCURE PHARMACEUTICALS LTD · 1 shipments · $51K | |||||||||||
| 11 | Dec 2025 | EMCURE PHARMA CHILE S.P.A | Chile | Tablet | 16.2K | NOS | $3.15 | $51K | NHAVA SHEVA SEA (JNPT) | San Antonio | SEA |
| SUPPLIER #4 — CIPLA LTD · 1 shipments · $42K | |||||||||||
| 12 | Dec 2025 | ROPACK | Canada | Tablet | 87.6K | NOS | $0.478 | $42K | MUMBAI AIR (SAHAR) | Montreal-Doraval Apt | AIR |
| SUPPLIER #5 — ANH PHARMACEUTICALS PVT LTD · 2 shipments · $24K | |||||||||||
| 13 | Dec 2025 | UNLISTED BUYER | Guatemala | Tablet | 486 | THD | $24.52 | $12K | NHAVA SHEVA SEA (JNPT) | Puerto Quetzal | SEA |
| 14 | Dec 2025 | UNLISTED BUYER | Guatemala | Tablet | 486 | THD | $24.52 | $12K | NHAVA SHEVA SEA (JNPT) | Puerto Quetzal | SEA |
| SUPPLIER #6 — ALEMBIC PHARMACEUTICALS LTD · 1 shipments · $11K | |||||||||||
| 15 | Oct 2025 | J. KNIPPER & COMPANY | United States | Tablet | 668.2K | TBS | $0.017 | $11K | MUNDRA SEA | NORFOLK | SEA |
| SUPPLIER #7 — WESTCOAST PHARMACEUTICAL WORKS LTD · 1 shipments · $7K | |||||||||||
| 16 | Oct 2025 | UNLISTED BUYER | Venezuela | Tablet | 7.9K | NOS | $0.862 | $7K | AHMEDABAD AIR | CARACAS | AIR |
10
PART VI — DRILL-DOWN · OCEANIA
Region: Oceania
1 countries · 3 shipments · $551.04 · 1 Indian suppliers · 1 buyers
SHIPMENTS
3
USD
$551.04
COUNTRIES
1
SUPPLIERS
1
BUYERS
1
HHI
10,000
concentrated
Top 1 destination countries in Oceania
1
Papua New Guinea (100.0%)
$551.04
Top 1 Indian suppliers into Oceania
1
ARIHANT EXPORTERS
$551.04
Top 1 Oceania importers
1
SESAGO HEALTH CARE LTD · Papua New Guinea
$551.04
Top 1 dosage forms
1
Tablet
$551.04
Monthly trend
| Month | Ships | USD | Avg/ship |
|---|---|---|---|
| Oct | 0 | $0.0000 | — |
| Nov | 0 | $0.0000 | — |
| Dec | 3 | $551.04 | $183.68 |
Shipment register · 3 rows · grouped by exporter
| # | Date | Importer | Country | Dosage | Qty | Unit | Unit $ | Total $ | Origin | Dest | Mode |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SUPPLIER #1 — ARIHANT EXPORTERS · 3 shipments · $551.04 | |||||||||||
| 1 | Dec 2025 | SESAGO HEALTH CARE LTD | Papua New Guinea | Tablet | 80 | PCS | $3.39 | $271.20 | NHAVA SHEVA SEA (JNPT) | Port Moresby | SEA |
| 2 | Dec 2025 | SESAGO HEALTH CARE LTD | Papua New Guinea | Tablet | 80 | PCS | $3.46 | $276.76 | NHAVA SHEVA SEA (JNPT) | Port Moresby | SEA |
| 3 | Dec 2025 | SESAGO HEALTH CARE LTD | Papua New Guinea | Tablet | 80 | PCS | $0.039 | $3.09 | NHAVA SHEVA SEA (JNPT) | Port Moresby | SEA |
10
PART VI — EVIDENCE REGISTER
Indian Supplier Directory
All 21 Indian leflunomide exporters — complete list ranked by USD
KEY TAKEAWAY
This directory lists every Indian company that shipped leflunomide in 2025-Q4.
S FOR SUPPLIERS
Find yourself and your competitors. Compare shipment count, USD, and destination regions.
B FOR BUYERS
Search for potential Indian suppliers. Filter by dosage form and destination region.
| # | Supplier | City | Ships | USD | Dosage forms | Primary regions |
|---|---|---|---|---|---|---|
| 1 | ZYDUS LIFESCIENCES LTD | BADDI | 9 | $422K | Tablet | Americas |
| 2 | ALEMBIC PHARMACEUTICALS LTD | GUJARAT | 19 | $312K | Tablet, filmtablets | Americas, Europe |
| 3 | TORRENT PHARMACEUTICALS LTD | AHMEDABAD. GUJARAT | 11 | $243K | Tablet | Africa, Asia |
| 4 | CAPLIN POINT LABORATORIES LTD | Puducherry | 1 | $194K | Tablet | Americas |
| 5 | EMCURE PHARMACEUTICALS LTD | PUNE-MAHARASHTRA | 4 | $187K | Tablet | Europe, Americas |
| 6 | KUSUM HEALTHCARE PVT LTD | KUSUM HEALTHCARE PRIVATE LIMITED | 6 | $133K | Tablet | Asia, Europe |
| 7 | CIPLA LTD | PAREL MUMBAI MAHARASHTRA | 1 | $42K | Tablet | Americas |
| 8 | ANH PHARMACEUTICALS PVT LTD | VADODARA | 2 | $24K | Tablet | Americas |
| 9 | ASPO PHARMACEUTICALS LLP | BADDI | 1 | $10K | Tablet | Asia |
| 10 | USV PVT LTD | MUMBAI | 1 | $8K | Tablet | Asia |
| 11 | WESTCOAST PHARMACEUTICAL WORKS LTD | AHMEDABAD | 1 | $7K | Tablet | Americas |
| 12 | AKRITI PHARMACEUTICALS PVT LTD | THANE (W) | 1 | $7K | Tablet | Asia |
| 13 | DEVLIFE CORP PVT LTD | MUMBAI | 1 | $3K | Tablet | Asia |
| 14 | BAKER & DAVIS PVT LTD | MUMBAI | 4 | $897.07 | Tablet | Asia |
| 15 | ARIHANT EXPORTERS | SURENDRANAGAR | 3 | $551.04 | Tablet | Oceania |
| 16 | DERRIC WOOD | SUBHASH PLACE | 8 | $161.72 | Tablet | Asia |
| 17 | M T MADON EXPORTS | MUMBAI | 1 | $126.94 | Tablet | Africa |
| 18 | IPCA LABORATORIES LTD | SILVASSA | 2 | $61.51 | Tablet | Asia |
| 19 | BABA AGENCIES | Chennai | 2 | $48.62 | Tablet | Asia |
| 20 | VEA IMPEX (I) PVT LTD | MUMBAI | 2 | $17.13 | Tablet | Asia |
| 21 | MDS ENTERPRISES | MUMBAI | 4 | $0.866 | Tablet | Asia |
10
PART VI — EVIDENCE REGISTER
Global Buyer Directory
All 30 global leflunomide importers — complete list ranked by USD
KEY TAKEAWAY
This directory lists every company that imported Indian leflunomide in 2025-Q4.
S FOR SUPPLIERS
Search for potential customers by country and dosage form.
B FOR BUYERS
Find your company and see which Indian supplier serves you.
| # | Buyer | Country | Ships | USD | Primary supplier | Dosage forms |
|---|---|---|---|---|---|---|
| 1 | ZYDUS PHARMACEUTICALS USA INC | United States | 8 | $378K | ZYDUS LIFESCIENCES LTD | Tablet |
| 2 | STADAPHARM GMBH | Germany | 8 | $222K | ALEMBIC PHARMACEUTIC… | Tablet |
| 3 | NEOETHICALS CIA LTDA DIRECCION | Ecuador | 1 | $194K | CAPLIN POINT LABORAT… | Tablet |
| 4 | TILLOMED LABORATORIES LTD | United Kingdom | 3 | $135K | EMCURE PHARMACEUTICA… | Tablet |
| 5 | JDS CO LTD | Myanmar | 1 | $105K | TORRENT PHARMACEUTIC… | Tablet |
| 6 | HATTON NATIONAL BANK PLC | Sri Lanka | 1 | $85K | TORRENT PHARMACEUTIC… | Tablet |
| 7 | FE BARAKA DORI FARM LLC | Uzbekistan | 1 | $75K | KUSUM HEALTHCARE PVT… | Tablet |
| 8 | EMCURE PHARMA CHILE S.P.A | Chile | 1 | $51K | EMCURE PHARMACEUTICA… | Tablet |
| 9 | PHARMACHEM PVT LTD | Nepal | 7 | $47K | TORRENT PHARMACEUTIC… | Tablet |
| 10 | J.D.S CO LTD | Myanmar | 5 | $43K | KUSUM HEALTHCARE PVT… | Tablet |
| 11 | ROPACK | Canada | 1 | $42K | CIPLA LTD | Tablet |
| 12 | ALIUD PHARMA GMBH | Germany | 5 | $37K | ALEMBIC PHARMACEUTIC… | Tablet, filmtablets |
| 13 | ALLOGA (NEDERLAND) B.VP.A. JAN DE R | Netherlands | 3 | $33K | ALEMBIC PHARMACEUTIC… | Tablet |
| 14 | J. KNIPPER & COMPANY | United States | 1 | $11K | ALEMBIC PHARMACEUTIC… | Tablet |
| 15 | ESRAR PHARMA | Yemen | 1 | $10K | ASPO PHARMACEUTICALS… | Tablet |
| 16 | LLP DARI-PHARM (KAZAKHSTAN) | Kazakhstan | 1 | $10K | KUSUM HEALTHCARE PVT… | Tablet |
| 17 | HEMAS PHARMACEUTICALS PVT LTD | Sri Lanka | 1 | $8K | USV PVT LTD | Tablet |
| 18 | ROYAL DISTRIBUTION CO LTD | Thailand | 1 | $7K | AKRITI PHARMACEUTICA… | Tablet |
| 19 | GLADPHARM LTD | Ukraine | 1 | $6K | KUSUM HEALTHCARE PVT… | Tablet |
| 20 | NOMECO HEALTHCARE LOGISTICS | Denmark | 1 | $5K | ALEMBIC PHARMACEUTIC… | Tablet |
| 21 | MEDOX PHARMACEUTICALS LTD | Kenya | 1 | $5K | TORRENT PHARMACEUTIC… | Tablet |
| 22 | CSP COURNON | France | 1 | $4K | ALEMBIC PHARMACEUTIC… | Tablet |
| 23 | TSAMPAKA PHARMACEUTICAL & MEDICAL | Bhutan | 1 | $3K | DEVLIFE CORP PVT LTD | Tablet |
| 24 | PHARMACEUTICAL AND CHEMICAL DISTRIB | Zimbabwe | 1 | $1K | TORRENT PHARMACEUTIC… | Tablet |
| 25 | ETEMAD MOSLEH LTD | Afghanistan | 1 | $688.02 | BAKER & DAVIS PVT LTD | Tablet |
| 26 | SESAGO HEALTH CARE LTD | Papua New Guinea | 3 | $551.04 | ARIHANT EXPORTERS | Tablet |
| 27 | EMIRATES POST COMPANY | United Arab Emirates | 8 | $161.72 | DERRIC WOOD | Tablet |
| 28 | ARROW TRADING FZE | United Arab Emirates | 2 | $139.17 | BAKER & DAVIS PVT LTD | Tablet |
| 29 | SALAMA PHARMACUTICALS LTD | Kenya | 1 | $126.94 | M T MADON EXPORTS | Tablet |
| 30 | VITAL RANK SDN BHD | Malaysia | 1 | $24.31 | BABA AGENCIES | Tablet |
This report covers 84 2025-Q4 Leflunomide shipments.
TransData Nexus tracks 3.37M+ shipments across all pharmaceuticals since 2020.
→ transdatanexus.com/pharmaceutical/leflunomide
Talk to our trade analyst
Need a custom leflunomide report or a deeper dive into any market? Our team is ready.
WhatsApp: +91 95950 78788 · transdatanexus.com
PHARMA TRADE INTELLIGENCE
Thank you for reading
This report is part of the TransData Nexus Pharma Trade Intelligence series, covering 366 pharmaceutical products exported from India.
Every figure is grounded in real commercial trade records — official customs filings and licensed databases. No surveys, no estimates, no fake data.
Need a custom report?
We can generate intelligence for any pharmaceutical product, any time period, any combination of source and destination countries.
Want deeper analysis?
Our team provides competitive intelligence, market entry strategy, and supply chain due diligence for pharma importers and exporters.
Scan for product page
WhatsApp: +91 95950 78788
Email: info@transdatanexus.com
Web: https://transdatanexus.com/pharmaceutical/leflunomide
© 2026 TransData Nexus. All rights reserved. This report is provided for informational purposes only.
Data sourced from official customs filings and licensed commercial trade databases.
Reproduction without permission is prohibited.
Explore the full Leflunomide product page
Live data, supplier directory, price trends, and trade route analysis